Under New CEO, Glaxo Will Leverage OTCs In Emerging Markets
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline will seed its growth in emerging markets with OTC drugs and other nonprescription products, according to Chris Viehbacher, the firm's North American Pharmaceuticals division president
You may also be interested in...
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.
People In Brief
Bristol-Myers exec to head Teva; GSK’s Witty now Sir Andrew; ISPE names Berg president; more People In Brief.